SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH M impact

Anaheim Bio Launches With €40 Million Series A Financing

Anaheim Bio launched with €40 million in Series A financing to advance ANA-1 for calcium pyrophosphate deposition disease into the clinic. The company spun out of Alesta Therapeutics before Alesta’s recent acquisition by BioMarin.

SquawkNews Desk

Related stories

Tripadvisor Reports Third-Quarter Loss of $2.66 per Share M impact | EQUITY | Nov 05, 2026, 12:22 PM UTC DTE Energy reports third-quarter earnings DTE Energy reported third-quarter earnings of $4. M impact | EQUITY | Nov 05, 2026, 12:07 PM UTC Appian Q3 Cloud Subscriptions Revenue Rises 20% to $136.4M Appian reported Q3 2026 cloud subscriptions revenue of $136.4 million, up 20% year over year. M impact | EQUITY | Nov 05, 2026, 12:07 PM UTC Tripadvisor Reports Third-Quarter Revenue of $436.4 Million Tripadvisor reported third-quarter revenue of $436.4 million. M impact | EQUITY | Nov 05, 2026, 12:06 PM UTC Borussia Dortmund Q1 Net Profit Falls to €11.9M Q1 revenue was €107.4M versus €107.0M a year earlier, while net profit fell to €11.9M from €22.9M. The company maintained its 2026/2027 net profit forecast of €0M to €10M. M impact | EQUITY | Nov 05, 2026, 12:06 PM UTC Asian Tech Stocks Tumble in Tokyo and Seoul; Hong Kong Surges South Korea’s KOSPI fell 5.3%, while Japan’s Nikkei 225 also declined. Hong Kong shares rose. M impact | EQUITY | Nov 05, 2026, 12:06 PM UTC